An aberrant accumulation of nuclear β-
catenin is closely associated with the augmentation of
cancer malignancy. In this work, we report that several microtubule-targeting agents (MTAs) such as
vinblastine,
taxol, and C12 (combretastatin-2-aminoimidazole analog) inhibit Wnt/β-
catenin signaling in
oral squamous cell carcinoma (OSCC). We showed that the inhibition of microtubule dynamics by MTAs decreased the level of β-
catenin by increasing Axin and
adenomatous polyposis coli levels and reducing the level of dishevelled. Furthermore, MTAs strongly reduced the localization of β-
catenin in the nucleus. The reduction in the level of nuclear β-
catenin was neither due to the degradation of β-
catenin in the nucleus nor due to an increase in the export of nuclear β-
catenin from the nucleus. A motor
protein kinesin-2 was found to assist the nuclear transportation of β-
catenin. Interestingly, Wnt/β-
catenin signaling antagonist treatment synergized with MTAs and the activators of Wnt/β-
catenin signaling antagonized with the MTAs. C12 potently suppressed the growth of 4-Nitroquinoline 1-oxide-induced OSCC in the tongue of C57 black 6 mice and also abrogated Wnt/β-
catenin signaling pathway in the
tumor. Our results provide evidence that the decrease in Wnt/β-
catenin signaling is an important antitumor effect of MTAs and the combined use of MTAs with Wnt/β-
catenin signaling antagonists could be a promising strategy for
cancer chemotherapy.